Insider buying last 90 days
No open-market insider purchases were filed for BRKR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BRKR insider filing, plotted on the chart in Gekko.Open BRKR in Gekko
NASDAQ: BRKR
Bruker (BRKR) Stock Analysis & Forecast
Sep 28 close
$63.28−0.90 (−1.4%)
Gekko Brief
AI summaryBruker moves this week on continued momentum in AI-linked demand and new product and order news. The company presented at the Bank of America Global Healthcare Conference and announced new timsUltra AIP and timsOmni workflows at the Human Proteome Organization World Congress 2026. CFO Gerald Herman pointed to AI-fueled semiconductor demand and a targeted Q4 revenue rebound, following stronger-than-expected organic order bookings and earnings per share in the prior quarter. Separately, UC Berkeley placed a multi-system order exceeding $6 million for high-field NMR instrumentation, and Bruker was noted among Wednesday's gainers with a 7.5% increase.
The stock closes at $63.28, down 1.4% on the day, and sits above both its 50-day ($58.58) and 200-day ($48.95) moving averages, with the 50-day above the 200-day. The GekkoIndex reads 52, placing it in the Neutral zone, with a five-day change of 0.3. Price stands 31% above Gekko Fair Value of $48.32. Trailing returns show 6.8% over one month, 6% over three months, 87.7% over six months, and 105.6% over the past year, against a 52-week range of $30.09 to $65.30.
Over the next 20 trading days, the next earnings report is due 2 November 2026, 34 days out, before market open, following a 6 May 2026 report that beat estimates ($0.31 vs $0.23) with a 15% reaction. No insider, Congress, or unusual options activity appears in their respective windows. Seasonality over five years shows a 5.8% average move across this period, rising in 2 of those years. Analyst consensus stands at 4 buy, 3 hold, 1 sell, with a consensus target of $60.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Bruker price vs fair value
Close $63.28200-day averageGekko Fair Value $48.32
Bruker quick facts
- Market cap
- $9.63B
- P/E ratio
- —
- Forward P/E
- 13.8
- EPS, TTM
- −$0.75
- Revenue, TTM
- $3.50B
- Profit margin
- -2%
- Dividend yield
- 0.31%
- Beta
- 1.26
- Volume
- 2.51M avg 2.25M
- 1-year return
- +105.6%
- Typical daily move
- ±5.1%
- Typical 20-day move
- ±7%
- 50-day average
- $58.58
- 200-day average
- $48.95
- Next earnings
- Nov 2 before open
- Shares outstanding
- 152.4M
Bruker swing-trade checklist
Bruker scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $63.28 is above the 50-day ($58.58) and 200-day ($48.95) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
52, Neutral
Reading 52 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
31.0% above
Price is 31% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 34 days
Next report Nov 2, 2026, 34 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+5.8% on average
From this point in the calendar, the next 20 trading days averaged +5.8% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Bruker stock chart and price history
Bruker closed at $63.28 on Sep 28, 2026, +105.6% over the past year, inside a 52-week range of $30.09 to $65.30.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +6.8%
- 3 months
- +6.0%
- 6 months
- +87.7%
- 1 year
- +105.6%
The full BRKR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BRKR in Gekko
Follow Bruker through every session
Put BRKR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BRKR in GekkoFree for 7 days. No credit card required.
About Bruker
Bruker designs, builds and sells scientific instruments used for research, analysis and diagnostics. Its offerings span mass spectrometry systems, X-ray equipment, atomic force microscopy tools and optical fluorescence microscopy, along with diagnostic products such as the MALDI Biotyper for pathogen identification, molecular test kits, DNA test strips and PCR-based testing, including solutions developed for SARS-CoV-2 detection.
The business is organized into three segments: Life Science, NANO, and Energy & Supercon Technologies. Life Science covers instruments and diagnostics for research and clinical use, along with products supporting multi-omics work in drug and biomarker discovery. NANO focuses on tools such as X-ray metrology, AFM defect detection, and equipment for photomask repair and cleaning. The Energy segment supplies superconducting materials, including metallic low-temperature superconductors, and related equipment such as synchrotron and beamline instrumentation. Bruker also works with Newomics Inc. on an LC-MS platform aimed at drug discovery.
Bruker was founded in 1991 and is headquartered in Billerica, Massachusetts. Its shares are listed on the NASDAQ under the ticker BRKR.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- bruker.com
Bruker GekkoIndex: the smart money zone
Bruker’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52, in the Neutral zone, up 0.3 points over five sessions.
52Neutral
Up 0.3 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 50 | +3.2% | +0.4% | ||
| Accumulation | 251 | −0.3% | −2.1% | ||
| Neutral (current zone) | 334 | −0.1% | +1.5% | ||
| Distribution | 31 | +1.2% | +3.5% | ||
| Selling | 6 | Too few readings yet | |||
Average BRKR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the BRKR price, zone by zone.Track BRKR in Gekko
Is Bruker stock overvalued? Gekko Fair Value
Bruker trades 31.0% above Gekko Fair Value of $48.32, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Bruker shares are worth, recalculated every trading day.
$48.32
Gekko Fair Value, Sep 29, 2026
31.0% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open BRKR in Gekko
Bruker insider and Congress trading
No open-market insider purchases were filed for Bruker, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in BRKR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for BRKR, plotted on the chart in Gekko.Open BRKR in Gekko
Buybacks
Bruker has been buying back its own shares.
- Bought back, quarter ended Mar 31, 2025
- $10.00M
- As a share of market cap
- 0.10%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
2of the funds Gekko tracks hold BRKR.
0added2opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Bruker earnings: next date and track record
Bruker reports on Nov 2, 2026, before the open (34 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 2, 2026
Expected before the open, 34 days away
- EPS estimate
- $0.42
- Revenue estimate
- $867.4M
4 of 8reports beat the EPS estimate
±7.5%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, May 6, 2026 AI summary
- What they said
- Bruker Q1 2026 results came in ahead of expectations despite U.S. academic demand softness, tariff, and currency headwinds. BSI segment bookings grew organically in the high-single-digits, with semiconductor metrology (>$300M revenue) and SciY software (~$50M) both seeing 20%+ organic bookings growth driven by AI demand. Security detection (~$70M expected revenue) and the BEST segment also showed strong momentum, with ~$600M in multi-year superconductor orders over five months.
- Guidance
- Management reconfirmed full-year 2026 financial outlook despite macro headwinds. Expects continued momentum in semiconductor metrology and security detection businesses, with U.S. academic demand recovery contingent on NIH funding environment improvement.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| May 6, 2026 | $0.31 est $0.23 | $823.4M est $795.6M | +15.0% |
| Feb 12, 2026 | $0.59 est $0.65 | $977.2M est $962.3M | −14.0% |
| Nov 3, 2025 | $0.45 est $0.32 | $860.5M est $964.6M | +3.7% |
| Aug 4, 2025 | $0.32 est $0.33 | $797.4M est $810.2M | −15.6% |
| May 7, 2025 | $0.47 est $0.46 | $801.4M est $819.9M | +2.7% |
| Feb 13, 2025 | $0.76 est $0.74 | $979.6M est $965.6M | −3.1% |
| Nov 5, 2024 | $0.60 est $0.60 | $864.4M est $859.4M | −0.6% |
| Aug 6, 2024 | $0.52 est $0.52 | $800.7M est $796.5M | −5.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Bruker stock forecast and analyst price targets
Analysts’ average 12-month price target for Bruker is $60.00, −5.2% from the last close, from 8 firms rating the stock in the last 90 days.
$60.00consensus 12-month target, −5.2% from the last close
Now $63.28Avg $60.00
Low $40High $70
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 25 | Barclays | $58 | −8.3% |
| Aug 5 | Bank of America Securities | — | — |
| Aug 5 | Wells Fargo | $55 | −13.1% |
| Aug 5 | Stifel Nicolaus | $50 | −21.0% |
| Aug 5 | Citi | $53 | −16.2% |
+1.5%average 20-day move after past Neutral readings
+5.8%average move over the next 20 trading days in the last 5 years
±5.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Bruker seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, Bruker averaged +5.8% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +5.4% | 3 of 5 |
| Next 10 trading days | +4.3% | 3 of 5 |
| Next 15 trading days | +5.1% | 3 of 5 |
| Next 20 trading days | +5.8% | 2 of 5 |
| Next 30 trading days | +10.3% | 3 of 5 |
For scale, BRKR’s typical 20-trading-day move in either direction is about 7%.
Bruker market cap and key statistics
Bruker’s market cap is $9.63B and revenue of $3.50B over the last twelve months.
Valuation
- Market cap
- $9.63B
- Forward P/E
- 13.8
- EPS, TTM
- −$0.75
- Gekko Fair Value
- $48.32
Trading
- Volume
- 2.51M
- Avg volume, 20 days
- 2.25M
- 52-week high
- $65.30
- 52-week low
- $30.09
- Shares outstanding
- 152.4M
Financials
- Revenue, TTM
- $3.50B
- Profit margin
- -2%
- Return on equity
- -3%
- Quarterly earnings growth, YoY
- −81.8%
Risk and income
- Beta
- 1.26
- Typical daily move
- ±5.1%
- Typical 20-day move
- ±7%
- Dividend yield
- 0.31%
Bruker stock news this week
Coverage of Bruker this week reads positive: 3 positive, 0 neutral and 0 negative headlines.
- Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology ResearchGuruFocus, Sep 28
- Bruker Sees AI-Fueled Semiconductor Demand, Targets Critical Q4 Revenue ReboundMarketBeat, Sep 26
- Arm leads Wednesday's losers with an 8.5% drop as Bruker tops the gainers24/7 Wall St., Sep 24
- Bruker Corporation (BRKR) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha, Sep 22
- UC Berkeley orders more than $6 million in research equipment from BrukerStock Titan, Sep 22
- Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeleywww.marketscreener.com, Sep 21
Bruker peers
Bruker’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 23.7% above |
| ABTAbbott Laboratories | Accumulation | 15.0% below |
| DHRDanaher | Distribution | 10.2% above |
| ISRGIntuitive Surgical | Neutral | 17.0% above |
| MDTMedtronic | Accumulation | 24.1% below |
| SYKStryker | Accumulation | 14.1% below |
A peer links to its own page where one exists.
Bruker stock FAQ
What is Bruker’s market cap?
Bruker’s market cap is $9.63B at the Sep 28, 2026 close of $63.28, with 152.4M shares outstanding.
What is the Bruker stock forecast?
The consensus analyst 12-month price target for Bruker is $60.00, −5.2% from the last close. Of the 8 firms that rated the stock in the last 90 days, 4 rate it a buy, 3 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Bruker stock overvalued or undervalued?
On Gekko’s estimate Bruker is overvalued: the Sep 28, 2026 close of $63.28 is 31.0% above Gekko Fair Value of $48.32. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Bruker report earnings next?
Bruker is expected to report on Nov 2, 2026, before the market opens (34 days away). Analysts expect earnings of $0.42 per share on revenue of $867.4M. Bruker beat the earnings estimate in 4 of its last 8 reports, moving 7.5% on average across the report.
What is Bruker’s 52-week high and low?
Bruker’s 52-week high is $65.30 and its 52-week low is $30.09; it closed at $63.28 on Sep 28, 2026, +105.6% over the past year. Over the last five years the shares peaked at $94.86 on Mar 21, 2024.
Is Bruker stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and seasonality) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Bruker the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.